Clinical Report: FDA approves tau PET imaging agent
Overview
The FDA has approved florquinitau F18 injection (TAUKLARIFY) for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer's disease. The approval is based on two blinded read studies involving over 500 participants, demonstrating high agreement rates in tau pathology detection.
Background
The approval of TAUKLARIFY is for the diagnostic evaluation of Alzheimer's disease, particularly in identifying tau neurofibrillary tangles. Accurate imaging of tau pathology is important for understanding the disease's progression and differentiating Alzheimer's from other forms of cognitive impairment.
Data Highlights
| Study | Participants | Positive Percent Agreement | Negative Percent Agreement |
|---|---|---|---|
| Study 1 | 279 | 80% - 88% | 98% - 99% |
| Study 2 | 338 | 68% - 82% | 93% - 99% |
Key Findings
- TAUKLARIFY is indicated for tau PET imaging in adults with cognitive impairment.
- Approval supported by two blinded read studies with over 500 participants.
- Positive percent agreement ranged from 68% to 88% across studies.
- Negative percent agreement ranged from 93% to 99%.
- Safety assessed in 1,734 participants, with low incidence of adverse effects.
- Negative scans do not exclude tau pathology; results should be interpreted in context.
Clinical Implications
TAUKLARIFY is indicated for tau PET imaging in adults with cognitive impairment. The interpretation of scan results must be contextualized within the broader clinical evaluation.
Conclusion
The approval of TAUKLARIFY enhances diagnostic capabilities for Alzheimer's disease.
Related Resources & Content
- Lantheus Holdings, Press Release, 2023 -- FDA approves tau PET imaging agent
- European Radiology — Fundamentals of PET Molecular Imaging in Dementia and Parkinsonism-Related Neurodegenerative Disorders
- Acta Neuropathologica — Tau Protein in Neurons and Oligodendrocytes, but Not Astrocytes, Correlates with In Vivo Tau PET Imaging in Patients with Primary Tauopathies
- the asco post — FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
- The ASCO Post — FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
- SNMMI and the Alzheimer’s Association Release Updated Appropriate Use Criteria for Amyloid and Tau P
- Joint EANM/SNMMI recommendations on the use of Tau PET imaging in Alzheimer's disease
- TAUVID (flortaucipir F 18 injection) Prescribing Information
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
